natgillin/translations-raw huggingface dataset:
As anaesthetics may affect renal perfusion, the use of parenteral fluid therapy during surgery should be considered to decrease potential renal complications when using NSAIDs peri-operatively. 
Anestetici mogu utjecati na perfuziju bubrega pa treba razmotriti parenteralnu primjenu tekućine tijekom kirurškog zahvata kako bi se smanjile potencijalne komplikacije bubrega prilikom perioperativne uporabe nesteroidnih protuupalnih lijekova.
No relevant effects on body weight, bleeding time or evidence of any gastrointestinal, kidney or liver toxicity were observed. 
Nisu primijećeni relevantno djelovanje na tjelesnu težinu, trajanje krvarenja ni dokazi toksičnosti za gastrointestinalni trakt, bubrege ili jetru.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each ml contains 20 mg robenacoxib as active substance and 1 mg sodium metabisulphite (E 223) as an antioxidant. 
Jedan ml sadržava 20 mg robenakoksiba kao djelatnu tvar i 1 mg natrijeva metabisulfita (E 223) kao antioksidans.
Concurrent administration of potentially nephrotoxic medicines should be avoided as there might be an increased risk of renal toxicity. 
Istodobnu primjenu potencijalno nefrotoksičnih lijekova treba izbjegavati jer može postojati povećani rizik od nefrotoksičnosti.
Diarrhoea or vomiting with blood were uncommon. 
Proljev ili povraćanje s krvlju bili su manje česti.
At a dose of 1-2 mg/kg body weight, robenacoxib tablets produced a marked inhibition of COX-2 activity in cats and had no effect on COX-1 activity. 
U dozi od 1 do 2 mg/kg tjelesne težine tablete robenakoksiba uzrokovale su znatnu inhibiciju aktivnosti COX-2 u mačaka i nisu imale učinak na aktivnost COX-1.
It is a potent and selective inhibitor of the cyclooxygenase 2 enzyme (COX-2). 
Snažan je i selektivan inhibitor enzima ciklooksigenaze 2 (COX-2).
After surgery, once daily treatment may be continued for up to two further days. 
Nakon kirurškog zahvata liječenje jedanput na dan može se nastaviti još sljedeća dva dana.
Clinical field studies showed that robenacoxib was well-tolerated by most cats for up to 12 weeks. 
Klinička terenska ispitivanja pokazala su da je većina mačaka mlađa od 12 tjedana pokazala dobru toleranciju na robenakoksib.
Increases in liver enzyme activities associated with clinical signs of anorexia, apathy or vomiting were uncommon. 
Porasti u aktivnostima jetrenih enzima povezani s kliničkim znakovima anoreksije, apatije ili povraćanja bili su manje česti.
At the recommended dosage (2 mg/kg), analgesic, anti-inflammatory and anti-pyretic effects were demonstrated in an inflammation model, and in clinical trials, robenacoxib reduced pain and inflammation in cats undergoing orthopaedic or soft tissue surgery. 
Pri preporučenoj dozi (2 mg/kg) dokazani su analgetički, protuupalni i antipiretički učinci na model upale, a u kliničkim ispitivanjima robenakoksib je ublažio bol i upalu u mačaka koje su bile podvrgnute ortopedskim kirurškim zahvatima ili zahvatima na mekom tkivu.
Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID). 
Robenakoksib je nesteroidni protuupalni lijek (NSAID).
Do not use together with non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, medicines commonly used in the treatment of pain, inflammation and allergies. 
Ne primjenjivati s nesteroidnim protuupalnim lijekovima (NSAID) ili kortikosteroidima, lijekovima koji se obično primjenjuju za liječenje bola, upale i alergija.
Tablets: 
Tablete:
Pain at injection site was commonly reported. 
Bol na mjestu injekcije često je prijavljivan.
Acute musculo-skeletal disorders: treat for up to 6 days. 
Liječenje akutnih poremećaja mišićno-koštanog sustava: do 6 dana.
A reduction in body weight gain was observed in treated animals. 
U tretiranih životinja primijećeno je smanjeno dobivanje na težini.
STATEMENT OF ACTIVE SUBSTANCES 20 mg/ml Robenacoxib 
SASTAV DJELATNIH TVARI 20 mg/ml robenakoksib
Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID) of the coxib class. 
Robenakoksib je nesteroidni protuupalni lijek (NSAID) iz klase koksiba.
At dosages ranging from 0.25 to 4 mg/kg, robenacoxib had analgesic, anti-inflammatory and anti-pyretic effects in an inflammation model with a rapid onset of action (1 h). 
Pri rasponu doziranja od 0,25 do 4 mg/kg robenakoksib je imao analgetičke, protuupalne i antipiretičke učinke na model upale s brzim početkom djelovanja (1 h).
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS NATURE/TYPE: Blister foil 
OSNOVNI PODACI KOJI SE MORAJU NALAZITI NA BLISTERIMA ILI TRAKAMA OSOBINE/TIP: Blister
10 to < 20 
10 do <20
INDICATION(S) Not applicable. 
INDIKACIJA(E) Nije primjenjivo.
In an inflammation model in cats, robenacoxib injection had analgesic, anti-inflammatory and anti-pyretic effects and a rapid onset of action (0.5 h). 
Kod modela upale u mačaka injekcije robenakoksiba imale su analgetičke, protuupalne i antipiretičke učinke i brz početak djelovanja (0,5 sata).
Concurrent use of other active substances that have a high degree of protein binding may compete with robenacoxib for binding and thus lead to toxic effects. 
Istodobna primjena drugih djelatnih tvari koje se izrazito vežu na proteine može izazvati naticanje tih tvari s robenakoksibom za vezanje na iste proteine te tako uzrokovati toksične učinke.
5 mg tablets: Robenacoxib 5 mg 10 mg tablets: Robenacoxib 10 mg 20 mg tablets: Robenacoxib 20 mg 40 mg tablets: Robenacoxib 40 mg 
tablete od 5 mg: robenakoksib 5 mg tablete od 10 mg: robenakoksib 10 mg tablete od 20 mg: robenakoksib 20 mg tablete od 40 mg: robenakoksib 40 mg
Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs). 
Ne primjenjivati istodobno s kortikosteroidima ili drugim nesteroidnim protuupalnim lijekovima (NSAID).
After intravenous administration robenacoxib was rapidly cleared from blood (CL of 0.44 L/kg/h in cats and 0.81 L/kg/h in dogs) with an elimination t1/2 of 1.1 h in cats and 0.8 h in dogs. 
Nakon intravenozne primjene robenakoksib se brzo eliminira iz krvi (CL od 0,44 l/kg/h u mačaka i 0,81 l/kg/h u pasa) s poluvremenom eliminacije od 1,1 h u mačaka i 0,8 h u pasa.
In case of accidental ingestion or self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 
U slučaju nehotičnog gutanja ili ubrizgavanja odmah potražite pomoć liječnika i pokažite mu uputu ili etiketu.
Robenacoxib is excreted predominantly via the biliary route in cats (∼70%) and dogs (∼65%) and the remainder via the kidneys. 
Robenakoksib se izlučuje uglavnom putem žuči u mačaka (∼70 %) i pasa (∼65 %), a ostatak putem bubrega.
Robenacoxib persists longer and in higher concentrations at sites of inflammation than in blood. 
Robenakoksib se zadržava dulje i u višim koncentracijama na mjestima upale nego u krvi.
Robenacoxib is excreted predominantly via the biliary route (∼70%) rather than via the kidneys (∼30%). 
Robenakoksib se izlučuje više putem žuči (∼70 %) nego putem bubrega (∼30 %).
Clear, colourless to slightly coloured (pink) liquid. 
Bistra bezbojna do blago obojena (ružičasta) tekućina.
Co-administration of robenacoxib non-flavoured tablets with food produced no delay in Tmax, but slightly lower values for Cmax (832 ng/ml) and AUC (782 ng·h/ml). 
Istodobna primjena tableta robenakoksiba bez umjetnog okusa s hranom nije uzrokovala odgodu u Tmax, ali su zabilježene lagano snižene vrijednosti za Cmax (832 ng/ml) i AUC (782 ng·h/ml).
Onsior tablets are flavoured and are taken voluntarily by most dogs. 
Tablete Onsior su aromatizirane te ih većina pasa uzima dobrovoljno.
Co-administration of robenacoxib tablets with one third of the daily food ration produced no change in Tmax (0.5 h), Cmax (1,201 ng/ml) or AUC (1383 ng·h/ml). 
Istodobna primjena tableta robenakoksiba s jednom trećinom dnevne porcije hrane nije uzrokovala promjenu u Tmax (0,5 h), Cmax (1,201 ng/ml) ili AUC (1383 ng·h/ml).
Robenacoxib is excreted predominantly via the biliary route (∼65%) and the remainder via the kidneys. 
Robenakoksib se izlučuje uglavnom putem žuči (∼65 %), a ostatak putem bubrega.
Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids, coxibs. 
Farmakoterapijska grupa: protuupalni i antireumatski proizvodi, nesteroidi, koksibi.
5 to < 10 
5 do <10
Each tablet contains 6 mg robenacoxib. 
Jedna tableta sadržava 6 mg robenakoksiba.
Onsior tablets are easy to administer and well accepted by most cats. 
Tablete Onsior jednostavne su za primjenu i većina mačaka ih dobro prihvaća.
Robenacoxib had analgesic and anti-inflammatory actions in an inflammation model in dogs with single oral doses ranging from 0.5 to 8 mg/kg, with an ID50 of 0.8 mg/kg and a rapid onset of action (0.5 h). 
Robenakoksib je imao analgetičke i protuupalne učinke s modelom upale u pasa s pojedinim dozama davanim kroz usta u rasponu od 0,5 do 8 mg/kg s ID50 od 0,8 mg/kg i s brzim početkom djelovanja (0,5 sati).
INDICATION(S) Not applicable 
INDIKACIJA(E) Nije primjenjivo
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. 
U slučaju nehotičnog gutanja odmah potražite pomoć liječnika i pokažite mu uputu ili etiketu.
NATURE/TYPE: Cardboard box 
OSOBINE/TIP: Staklena bočica
If use cannot be avoided, these dogs require careful monitoring. 
Ako se primjena proizvoda ne može izbjeći, takve pse potrebno je pomno nadzirati.
2.5 to < 5 
2,5 do <5
2.5 to < 6 
2,5 do <6
Repeated subcutaneous administration at dosages of 2-20 mg/kg produced no change in the blood profile, with neither bioaccumulation of robenacoxib nor enzyme induction. 
Opetovane subkutane primjene lijeka u dozama od 2 do 20 mg/kg nisu uzrokovale promjene u krvnoj slici niti su zabilježene bioakumulacija robenakoksiba ili indukcija enzima.
In clinical trials robenacoxib tablets reduced the lameness and inflammation of dogs with chronic osteoarthritis. 
U kliničkim ispitivanjima tablete robenakoksiba smanjile su šepanje i upalu u pasa s kroničnim osteoartritisom.
Robenacoxib is cleared rapidly from blood (CL 0.81 L/kg/h) with an elimination t1/2 of 0.7 h after intravenous administration. 
Robenakoksib se brzo eliminira iz krvi (CL 0,81 l/kg/h) s poluvremenom eliminacije t1/2 od 0,7 h nakon intravenozne primjene.
Vomiting was very commonly reported, and anorexia, diarrhoea, lethargy and inappropriate defecation were commonly reported in field studies with treatment up to 3 months in cats with chronic musculo-skeletal disorder, with similar frequencies in the Onsior and placebo treated cats. 
Povraćanje je prijavljivano vrlo često, a anoreksija, proljev, letargija i neodgovarajuća defekacija često su prijavljivani u terenskim ispitivanjima s terapijom od najviše 3 mjeseca u mačaka s kroničnim mišićno-koštanim poremećajem, sa sličnom učestalošću u mačaka koje su dobivale Onsior i mačaka koje su dobivale placebo.
This product reduced in clinical trials pain and inflammation in cats and dogs undergoing orthopaedic or soft tissue surgery. 
Proizvod je u kliničkim ispitivanjima ublažio bol i upalu u mačaka i pasa koji su bili podvrgnuti ortopedskim kirurškim zahvatima ili zahvatima na mekom tkivu.
The pharmacokinetics of robenacoxib injection do not differ between male and female cats and dogs, and are linear over the range of 0.25-4 mg/kg in dogs. 
Nema razlike između farmakokinetike robenakoksiba između ženki i mužjaka pasa i mačaka te su u obama slučajevima linearne u rasponu od 0,25 do 4 mg/kg u pasa.
In cats robenacoxib is extensively metabolised by the liver. 
U mačaka se robenakoksib u velikoj mjeri metabolizira u jetri.
It selectively inhibits the cyclooxygenase 2 enzyme (COX-2), which is responsible for pain, inflammation or fever. 
Selektivno inhibira enzim ciklooksigenazu 2 (COX-2) koji je odgovoran za bol, upalu ili groznicu.
Robenacoxib is extensively metabolised by the liver in cats and dogs. 
Robenakoksib se u velikoj mjeri metabolizira u jetri mačaka i pasa.
In healthy cats treated with or without the diuretic furosemide, concomitant administration of Onsior with the ACE inhibitor benazepril for 7 days was not associated with any negative effects on plasma aldosterone concentrations, plasma renin activity or glomerular filtration rate. 
U zdravih mačaka tretiranih diuretikom furosemidom ili mačaka koje nisu njime tretirane istodobna primjena Onsiora s ACE inhibitorom benazeprilom od 7 dana nije bila povezana ni s kakvim negativnim učincima na koncentracije aldosterona u plazmi, reninsku aktivnost plazme ni stopu glomerularne filtracije.
Multi-dose amber glass vial containing 20 ml solution for injection, closed with a rubber stopper and sealed with an aluminium cap. One vial packed in a cardboard box. 
Višedozna žuta staklena bočica koja sadržava 20 ml otopine za injekciju zatvorena gumenim čepom i aluminijskim poklopcem.
COX-1 is the constitutive form of the enzyme and has protective functions, e.g. in the gastrointestinal tract and kidneys. 
COX-1 sastavni je dio enzima i ima zaštitne funkcije, primjerice u probavnom sustavu i bubrezima.
Repeated oral administration of robenacoxib to dogs at dosages of 2-10 mg/kg for 6 months produced no change in the blood profile, with neither accumulation of robenacoxib nor enzyme induction. 
Ponovljena primjena robenakoksiba kroz usta u pasa u dozama od 2 do 10 mg/kg tijekom 6 mjeseci nije uzrokovala promjenu krvne slike niti je zabilježena akumulacija robenakoksiba ili indukcija enzima.
No safety data in the target population and no efficacy data in general exist for the combined treatment of robenacoxib and benazepril. 
Za kombiniranu terapiju robenakoksibom i benazeprilom ne postoje sigurni podaci u ciljnoj populaciji niti podaci o djelotvornosti općenito.
Slight pain at injection site was commonly reported. 
Blagi bol na mjestu injekcije često je prijavljivan.
In clinical trials in cats, robenacoxib tablets reduced pain and inflammation associated with acute musculo-skeletal disorders and reduced the need for rescue treatment when given as premedication in case of orthopaedic surgery, in combination with opioids. 
U kliničkim ispitivanjima na mačkama tablete robenakoksiba ublažile su bol i upalu povezane s akutnim mišićno koštanim poremećajima te su smanjile potrebu za terapijom spašavanja kad su se davale kao premedikacija u slučaju ortopedskih kirurških zahvata, u kombinaciji s opioidima.
In small children, accidental ingestion increases the risk for NSAID adverse effects. 
U male djece slučajno gutanje povećava rizik od nuspojava nesteroidnih protuupalnih lijekova.
After a dosage of 2 mg/kg a Tmax of 1 h (cats and dogs), a Cmax of 1,464 ng/ml (cats) and 615 ng/ml (dogs), and an AUC of 3,128 ng·h/ml (cats) and 2,180 ng·h/ml (dogs) is obtained. 
Nakon doziranja od 2 mg/kg postiže se Tmax od 1 h (mačke i psi), Cmax od 1464 ng/ml (mačke) i 615
In artificially induced inflammation in dogs, robenacoxib reduced pain and inflammation with single oral doses ranging from 0.5 to 8 mg/kg and a rapid onset of action (0.5 h). 
Kod umjetno izazvane upale u pasa robenakoksib je smanjio bol i upalu u pojedinim oralnim dozama u rasponu od 0,5 do 8 mg/kg i s brzim početkom djelovanja (0,5 h).
If use cannot be avoided, these animals require careful monitoring and fluid therapy. 
Ako se primjena ne može izbjeći, potrebno je pomno nadzirati te životinje te im davati tekućinu.
Robenacoxib is rapidly cleared from blood (CL 0.44 L/kg/h) with an elimination t1/2 of 1.1 h after intravenous administration. 
Robenakoksib se brzo eliminira iz krvi (CL 0,44 l/kg/h) s poluvremenom eliminacije od 1,1 sati nakon intravenozne primjene.
Robenacoxib has a relatively small volume of distribution (Vss of 190 ml/kg in cats and 240 ml/kg in dogs) and is highly bound to plasma proteins (>99%). 
Robenakoksib ima relativno mali volumen distribucije (Vss 190 ml/kg u mačaka i 240 ml/kg u pasa) te se izrazito veže za bjelančevine plazme (>99 %).
5 mg tablet: 
tablete od 10 mg:
Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and accordingly a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior. 
Prethodno liječenje drugim protuupalnim lijekovima može rezultirati dodatnim ili pojačanim neželjenim učincima, stoga prije početka liječenja proizvodom Onsior treba prekinuti liječenje takvim lijekovima na najmanje 24 sata.
The interchangeable use of Onsior tablets and Onsior solution for injection has been tested in a target animal safety study and was shown to be well tolerated by the cats. 
Naizmjenična uporaba tableta Onsior i otopine za injekcije Onsior ispitana je u ispitivanju sigurnosti ciljnih životinja te se pokazalo da je mačke dobro podnose.
Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and, accordingly, a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior. 
Prethodno liječenje drugim protuupalnim lijekovima može rezultirati dodatnim ili pojačanim neželjenim učincima, stoga prije početka liječenja proizvodom Onsior prekinuti liječenje takvim lijekovima na najmanje 24 sata.
After oral administration of robenacoxib tablets at approximately 2 mg/kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 h, a Cmax of 1,159 ng/ml and an AUC of 1,337 ng·h/ml. 
Nakon peroralne primjene tableta robenakoksiba u dozama od približno 2 mg/kg bez hrane vršne koncentracije u krvi postignute su brzo, s Tmax od 0,5 sati, Cmax od 1,159 ng/ml i AUC od 1,337
COX-2 activity and had no effect on COX-1 activity in dogs at oral doses ranging from 0.5 to 4 mg/kg. 
Robenakoksib je uzrokovao znatnu inhibiciju aktivnosti COX-2 i nije imao učinak na aktivnost COX-1 u pasa kod doza davanim kroz usta u rasponu od 0,5 do 4 mg/kg tjelesne težine.
In healthy young dogs aged 6 months, once daily subcutaneous administration of robenacoxib at doses of 2 (recommended therapeutic dose; RTD), 6 (3 times RTD), and 20 mg/kg (10 times RTD) for 9 administrations over a 5 week period (3 cycles of 3 consecutive once daily injections) did not produce any signs of toxicity, including gastrointestinal, kidney or liver toxicity and had no effect on bleeding time. 
U zdravih mladih pasa u dobi od 6 mjeseci subkutana primjena robenakoksiba jedanput na dan u dozama od 2 (preporučena terapijska doza; PTD), 6 (tri puta PTD) i 20 mg/kg (10 puta PTD) za 9 primjena tijekom pet tjedana (3 ciklusa od 3 uzastopne injekcije jedanput na dan) nije uzrokovala nikakve znakove toksičnosti, uključujući gastrointestinalnu toksičnost, toksičnost bubrega ili jetre, i nije utjecala na vrijeme krvarenja.
Cardboard box containing 6 x 1, 12 x 1, 30 x 1 or 60 x 1 tablets in Alu/Alu perforated unit dose blisters. 
Kartonska kutija koja sadržava 6 x 1, 12 x 1, 30 x 1 ili 60 x 1 tableta u Alu/Alu perforiranim blisterima s jediničnim dozama.
The recommended dose of robenacoxib is 1 mg/kg body weight with a range 1-2.4 mg/kg. 
Preporučena doza robenakoksiba je 1 mg/kg tjelesne težine s rasponom od 1 - 2,4 mg/kg.
For the reduction of moderate pain and inflammation associated with orthopaedic surgery in cats. 
Za ublažavanje umjerenog bola i upale povezanih s ortopedskim kirurškim zahvatima u mačaka.
The interchangeable use of Onsior tablets and Onsior solution for injection has been tested in a target animal safety study and was shown to be well tolerated by cats. 
Naizmjenična uporaba tableta Onsior i otopine za injekcije Onsior ispitana je u ispitivanju sigurnosti ciljnih životinja se pokazalo da mačke dobro podnose.
For cats, Onsior solution for injection or tablets may be used interchangeably in accordance with the indications and directions of use approved for each pharmaceutical form. 
U mačaka se Onsior otopina za injekcije ili tablete mogu naizmjenično upotrebljavati u skladu s indikacijama i uputama za uporabu odobrenim za svaki farmaceutski oblik.
No changes in the QT interval were observed after a single intravenous administration of 2 or 4 mg/kg robenacoxib to anaesthetised healthy cats. 
Nisu uočene promjene QT intervala nakon jedne intravenozne primjene 2 ili 4 mg/kg robenakoksiba na anesteziranim zdravim mačkama.
Gastrointestinal adverse events were reported very commonly, but most cases were mild and recovered without treatment. 
Gastrointestinalne nuspojave prijavljivane su vrlo često, ali većina slučajeva bila je blaga i povukla se bez liječenja.
Gastrointestinal adverse events (vomiting, soft faeces or diarrhoea) were commonly reported, but most cases were mild and recovered without treatment. 
Gastrointestinalne nuspojave (povraćanje, mekana stolica ili proljev) zabilježene su često, ali većina slučajeva bila je blaga i prošla je bez liječenja.
COX-2 is the inducible form of the enzyme which is responsible for the production of mediators including PGE2 which induce pain, inflammation or fever. 
COX-2 je inducibilni oblik enzima odgovoran za generiranje medijatora, uključujući PGE2 koji inducira bol, upalu ili groznicu.
Yeast powder Cellulose, microcrystalline Flavour, artificial beef Cellulose, powdered Povidone (K-30) Crospovidone Silica, colloidal anhydrous Magnesium stearate 
Umjetni okus govedine Celuloza u prahu Povidon (K-30) Krospovidon
Robenacoxib has a relatively small volume of distribution (Vss 190 ml/kg) and is highly bound to plasma proteins (>99%). 
Robenakoksib ima relativno mali volumen distribucije (Vss 190 ml/kg) te se izrazito veže za bjelančevine plazme (>99 %).
A dose-dependent increase in the QT interval, a decreased heart rate and corresponding increased respiratory rate were observed in laboratory studies. 
U laboratorijskim ispitivanjima zabilježeni su povećanje QT intervala povezano s doziranjem, smanjen broj otkucaja srca i odgovarajuće povećanje brzine disanja.
Robenacoxib has a relatively small volume of distribution (Vss 240 ml/kg) and is highly bound to plasma proteins (>99%). 
Robenakoksib ima relativno mali volumen distribucije (Vss 240 ml/kg) te se izrazito veže za bjelančevine plazme (>99 %).
Onsior 5 mg tablets for dogs Onsior 10 mg tablets for dogs Onsior 20 mg tablets for dogs Onsior 40 mg tablets for dogs 
Onsior 5 mg tablete za pse Onsior 10 mg tablete za pse Onsior 20 mg tablete za pse Onsior 40 mg tablete za pse
For the treatment of pain and inflammation associated with chronic osteoarthritis in dogs. 
Za liječenje bola i upale povezanih s kroničnim osteoartritisom u pasa.
Cardboard box containing 7, 14, 28 or 70 tablets in Alu/Alu blisters, 30 x 1 tablets in Alu/Alu perforated unit dose blisters or 60 x 1 tablets in Alu/Alu perforated unit dose blisters. 
Kartonska kutija koja sadržava 7, 14, 28 ili 70 tableta u Alu / Alu blisteru, 30 x 1 tableta u Alu / Alu perforiranim blisterima s jediničnim dozama ili 60 x 1 tableta u Alu / Alu perforiranim blisterima s jediničnim dozama.
As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised animals. 
Kao i s bilo kojim nesteroidnim protuupalnim lijekom, predoziranje može uzrokovati gastrointestinalnu, bubrežnu ili jetrenu toksičnost u osjetljivih životinja ili životinja oslabljenog imuniteta.
Do not use in dogs suffering from stomach ulcer or with liver disease. 
Ne primjenjivati u pasa koji pate od ulceracija u probavnom sustavu ili od bolesti jetre.
PACKAGE LEAFLET: Onsior 20 mg/ml solution for injection for cats and dogs 
Onsior 20 mg/ml otopina za injekcije za mačke i pse
After oral administration of robenacoxib flavoured tablets at 1 mg/kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 h, a Cmax of 1,124 ng/ml and an AUC of 1,249 ng·h/ml. 
Nakon primjene tableta robenakoksiba s umjetnim okusom u dozama od 1 mg/kg kroz usta bez hrane, vršne koncentracije u krvi postignute su brzo, s Tmax od 0,5 sati, Cmax od 1124 ng/ml i AUC od 1249 ng·h/ml.
The recommended dose of robenacoxib is 1 mg/kg body weight with a range 1-2 mg/kg. 
Preporučena doza robenakoksiba je 1 mg/kg tjelesne težine u rasponu od 1 do 2 mg/kg.
If use cannot be avoided, these cats require careful monitoring. 
Ako se primjena proizvoda ne može izbjeći, potrebno je pomno nadzirati takve mačke.